The expression of SETD6 is amplified in about 10% of cases of breast cancer according to a study using a patient xenograft model [18] and is required for cellular proliferation in both ER+ and ER− breast cancer cell models [19], suggesting an important role in driving breast cancer progression. Here, SETD6 is linked to breast carcinoma.